DrugRepV_1350 | Tobramycin | Antiinfectives For Systemic Use; Sensory Organ | Pseudomonas Aeruginosa (Bacteria) lung infections | Sinus infections | Zika virus | MEX_I_7 | NA | Fluorescence-based assay | Decrease (47.055 %) | Approved, Investigational | 27476412 |
DrugRepV_2474 | Sulfisoxazole | Antiinfectives For Systemic Use; Sensory Organ | Urinary tract infections | Meningococcal meningitis | Acute otitis media | Trachoma | Inclusion conjunctivitis | Nocardiosis | Chancroid | Toxoplasmosis | Malaria | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | No significant decrease (0.58656517 %) | Approved, Vet approved | 27742486 |
DrugRepV_2480 | Vidarabine | Antiinfectives For Systemic Use; Sensory Organ | Viral infections (Chickenpox, Herpes simplex, Zoster and varicella zoster) | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | No significant decrease (0.36868435 %) | Approved | 27742486 |
DrugRepV_2551 | Tobramycin | Antiinfectives For Systemic Use; Sensory Organ | Pseudomonas Aeruginosa (Bacteria) lung infections | Sinus infections | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | Increase (-0.8678849 %) | Approved, Investigational | 27742486 |
DrugRepV_8157 | Vidarabine | Antiinfectives For Systemic Use; Sensory Organ | Viral infections (Chickenpox, Herpes simplex, Zoster and varicella zoster) | Vaccinia virus | NA | | NA | Decrease (99.7 %) | Approved | 32708182 |